As per the WHO statistics, the global prevalence of diabetes, increased to 8.5% in adults over the age of 18 in the year 2014 from 4.7% in the year 1980. This rising prevalence of chronic diseases has led to an increase in the demands for improved treatments and diagnostic services. For the treatment of these types of diseases, various novel ways to administer drugs have been developed such as needle-free injectors, autoinjectors, pen injectors, and pre-filled syringes. According to the latest market intelligence report by BIS Research titled, ‘Global Injectable Drug Delivery Market- Analysis and Forecast (2018-2025),’ the market was estimated at $16.73 billion in 2016. The market for drug injectable is anticipated to grow over $37.47 billion by the year 2025. This significant growth is majorly attributed to the increase in the chronic diseases along with the rise in the geriatric population.
A prefilled syringe is a comparatively new product in the pharmaceutical market which has accelerated its pace gradually and has become an important option in the packaging and delivery of injectable drug products. This prefilled syringe is an innovation in parenteral packaging, which contains a single dose in a primary sterile container and a delivery system which is filled aseptically with an injectable drug. Primarily, the most commonly used therapeutic categories in the prefilled syringe format are anticoagulants, antivirals, anaphylaxis, hematopoietic, monoclonal antibodies and vaccines. Prefilled syringes are helping pharmaceutical companies to minimize drug wastage and increase product lifespan, while helping the patients to self-administer injectable drugs at their homes.